This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: You can take Mounjaro at any time of day. The best ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ AutoinjectorWESTLAKE ...

Genentech, a subsidiary of the Roche Group, has received the US Food and Drug Administration’s (FDA) accelerated approval for Lunsumio VELO subcutaneous (SC) formulation to treat adult patients with ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...